Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America
Background: Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up. Regarding treatment, guidelines consider second generation antihistamines as the cornerstone in therapy for chronic urticaria (C...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | World Allergy Organization Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455119300985 |
id |
doaj-ccae17d16247409b943a2a0b9af147b5 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ivan Cherrez-Ojeda Marcus Maurer Jonathan A. Bernstein Emanuel Vanegas Miguel Felix German D. Ramon Luis Felipe Ensina José Ignacio Larco Sousa Edgar Emilio Matos Benavides R. Cardona Villa P. Latour Staffeld Blanca María Morfin-Maciel Jose Mori Paul Wilches C Valeria L. Mata Annia Cherrez |
spellingShingle |
Ivan Cherrez-Ojeda Marcus Maurer Jonathan A. Bernstein Emanuel Vanegas Miguel Felix German D. Ramon Luis Felipe Ensina José Ignacio Larco Sousa Edgar Emilio Matos Benavides R. Cardona Villa P. Latour Staffeld Blanca María Morfin-Maciel Jose Mori Paul Wilches C Valeria L. Mata Annia Cherrez Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America World Allergy Organization Journal |
author_facet |
Ivan Cherrez-Ojeda Marcus Maurer Jonathan A. Bernstein Emanuel Vanegas Miguel Felix German D. Ramon Luis Felipe Ensina José Ignacio Larco Sousa Edgar Emilio Matos Benavides R. Cardona Villa P. Latour Staffeld Blanca María Morfin-Maciel Jose Mori Paul Wilches C Valeria L. Mata Annia Cherrez |
author_sort |
Ivan Cherrez-Ojeda |
title |
Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America |
title_short |
Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America |
title_full |
Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America |
title_fullStr |
Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America |
title_full_unstemmed |
Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America |
title_sort |
learnings from real-life experience of using omalizumab for chronic urticaria in latin america |
publisher |
Elsevier |
series |
World Allergy Organization Journal |
issn |
1939-4551 |
publishDate |
2019-01-01 |
description |
Background: Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up. Regarding treatment, guidelines consider second generation antihistamines as the cornerstone in therapy for chronic urticaria (CU), while other drugs, such as omalizumab, are conceived as second-line alternatives. In regards to omalizumab, despite advances in the management of CU, there are still open questions about timing, dosing, and objective measures for clinical response. This study was designed to portray the use of patient-reported outcomes (PROs) in chronic urticaria management, as well as the effectiveness and treatment patterns of omalizumab in CU, as seen in a real-life setting in Latin America. Methods: This is a retrospective observational study, involving 72 Latin American patients with chronic urticaria treated with omalizumab. Patient reported outcomes and treatment patterns, response, quality of life improvement and discontinuation were analyzed. Results: From the 72 patients, 91.7% (n = 66) were assessed through PROs, where urticaria control test (UCT) was the most used (79.2%; n = 57). Overall, 80.0% (n = 44) responded to omalizumab at some point of the treatment. Omalizumab 300 mg was associated with earlier response compared to lower doses. Regardless of dosage, most patients assessed with CU-Q2oL improved quality of life (80.8%; n = 21). With respect to omalizumab discontinuation, 20.8% (n = 15) patients interrupted omalizumab before the 3rd month of treatment (p = .000). Conclusions: The present study highlights how the use of PROs and omalizumab in Latin America differ from guidelines’ recommendations and clinical trials. Even though most patients were initiated under omalizumab 300 mg, most of them finished with lower doses. Regardless of dosage, most patients responded to omalizumab and improved quality of life at some point during treatment. However, such features were seen earlier with omalizumab 300 mg. Regarding treatment discontinuation, one-fifth of patients interrupted omalizumab before the third month. Keywords: Chronic spontaneous urticaria, Patient-reported outcomes, Omalizumab, Quality of life, Latin America |
url |
http://www.sciencedirect.com/science/article/pii/S1939455119300985 |
work_keys_str_mv |
AT ivancherrezojeda learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT marcusmaurer learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT jonathanabernstein learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT emanuelvanegas learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT miguelfelix learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT germandramon learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT luisfelipeensina learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT joseignaciolarcosousa learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT edgaremiliomatosbenavides learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT rcardonavilla learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT platourstaffeld learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT blancamariamorfinmaciel learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT josemori learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT paulwilchesc learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT valerialmata learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica AT anniacherrez learningsfromreallifeexperienceofusingomalizumabforchronicurticariainlatinamerica |
_version_ |
1724990270604312576 |
spelling |
doaj-ccae17d16247409b943a2a0b9af147b52020-11-25T01:53:33ZengElsevierWorld Allergy Organization Journal1939-45512019-01-01122Learnings from real-life experience of using omalizumab for chronic urticaria in Latin AmericaIvan Cherrez-Ojeda0Marcus Maurer1Jonathan A. Bernstein2Emanuel Vanegas3Miguel Felix4German D. Ramon5Luis Felipe Ensina6José Ignacio Larco Sousa7Edgar Emilio Matos Benavides8R. Cardona Villa9P. Latour Staffeld10Blanca María Morfin-Maciel11Jose Mori12Paul Wilches C13Valeria L. Mata14Annia Cherrez15Universidad Espíritu Santo, Samborondón, Ecuador; Respiralab, Respiralab Research Group, Guayaquil, Ecuador; Corresponding author. Iván Chérrez Ojeda, Universidad Espíritu Santo, Km. 2.5 vía La Puntilla, Samborondón, Ecuador. Código postal: 0901-952.Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, GermanyUniversity of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati, OH, United StatesUniversidad Espíritu Santo, Samborondón, Ecuador; Respiralab, Respiralab Research Group, Guayaquil, EcuadorUniversidad Espíritu Santo, Samborondón, Ecuador; Respiralab, Respiralab Research Group, Guayaquil, EcuadorInstituto de Alergia e Inmunología del Sur, Bahía Blanca, Prov. de Buenos Aires, ArgentinaFederal University of São Paulo, São Paulo, BrazilClínica San Felipe, Lima, PeruCentro De Referencia Nacional de Alergia Asma e Inmunologia – Insn, Lima, PeruUniversidad de Antioquia, Medellín, ColombiaCentro Avanzado de Alergia y Asma de Santo Domingo, Santo Domingo, Dominican Republic; Universidad Nacional Pedro Henriquez Ureña, Santo Domingo, Dominican RepublicHospital San Angel Inn Chapultepec, Ciudad de Mexico, MexicoClínica San Borja, Lima, PeruUnidad de Asma y Alergia del Hospital Monte Sinai, Cuenca, EcuadorUniversidad Espíritu Santo, Samborondón, Ecuador; Respiralab, Respiralab Research Group, Guayaquil, EcuadorRespiralab, Respiralab Research Group, Guayaquil, Ecuador; University Hospital, Dermatology Department, Rostock, GermanyBackground: Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up. Regarding treatment, guidelines consider second generation antihistamines as the cornerstone in therapy for chronic urticaria (CU), while other drugs, such as omalizumab, are conceived as second-line alternatives. In regards to omalizumab, despite advances in the management of CU, there are still open questions about timing, dosing, and objective measures for clinical response. This study was designed to portray the use of patient-reported outcomes (PROs) in chronic urticaria management, as well as the effectiveness and treatment patterns of omalizumab in CU, as seen in a real-life setting in Latin America. Methods: This is a retrospective observational study, involving 72 Latin American patients with chronic urticaria treated with omalizumab. Patient reported outcomes and treatment patterns, response, quality of life improvement and discontinuation were analyzed. Results: From the 72 patients, 91.7% (n = 66) were assessed through PROs, where urticaria control test (UCT) was the most used (79.2%; n = 57). Overall, 80.0% (n = 44) responded to omalizumab at some point of the treatment. Omalizumab 300 mg was associated with earlier response compared to lower doses. Regardless of dosage, most patients assessed with CU-Q2oL improved quality of life (80.8%; n = 21). With respect to omalizumab discontinuation, 20.8% (n = 15) patients interrupted omalizumab before the 3rd month of treatment (p = .000). Conclusions: The present study highlights how the use of PROs and omalizumab in Latin America differ from guidelines’ recommendations and clinical trials. Even though most patients were initiated under omalizumab 300 mg, most of them finished with lower doses. Regardless of dosage, most patients responded to omalizumab and improved quality of life at some point during treatment. However, such features were seen earlier with omalizumab 300 mg. Regarding treatment discontinuation, one-fifth of patients interrupted omalizumab before the third month. Keywords: Chronic spontaneous urticaria, Patient-reported outcomes, Omalizumab, Quality of life, Latin Americahttp://www.sciencedirect.com/science/article/pii/S1939455119300985 |